250 related articles for article (PubMed ID: 27230636)
1. Obesity, Diabetes, and Cardiovascular Diseases: A Compendium.
Scherer PE; Hill JA
Circ Res; 2016 May; 118(11):1703-5. PubMed ID: 27230636
[No Abstract] [Full Text] [Related]
2. Diabetes: Time for reconciliation between cardiologists and diabetologists.
Scheen AJ
Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401
[No Abstract] [Full Text] [Related]
3. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.
Mannucci E; Monami M; Ceriello A; Rotella CM
Nutr Metab Cardiovasc Dis; 2017 Apr; 27(4):375-377. PubMed ID: 28242233
[No Abstract] [Full Text] [Related]
4. Relationships between obesity, glycemic control, and cardiovascular risk factors: a pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage.
Vázquez LA; Rodríguez Á; Salvador J; Ascaso JF; Petto H; Reviriego J
BMC Cardiovasc Disord; 2014 Nov; 14():153. PubMed ID: 25361574
[TBL] [Abstract][Full Text] [Related]
5. Diabetes Mellitus and Its Cardiovascular Complications: New Insights into an Old Disease.
Sardu C; De Lucia C; Wallner M; Santulli G
J Diabetes Res; 2019; 2019():1905194. PubMed ID: 31236416
[No Abstract] [Full Text] [Related]
6. Weight change and risk of cardiovascular disease among adults with type 2 diabetes: more than 14 years of follow-up in the Tehran Lipid and Glucose Study.
Moazzeni SS; Hizomi Arani R; Deravi N; Hasheminia M; Khalili D; Azizi F; Hadaegh F
Cardiovasc Diabetol; 2021 Jul; 20(1):141. PubMed ID: 34253199
[TBL] [Abstract][Full Text] [Related]
7. Is Metabolic and Bariatric Surgery a Population Solution for Obesity and Type 2 Diabetes?
Blackstone RP
JAMA Surg; 2015 Dec; 150(12):1124-5. PubMed ID: 26375987
[No Abstract] [Full Text] [Related]
8. Is glycemic control a quinidine-like intervention?
Bloomgarden ZT
J Diabetes; 2014 Sep; 6(5):387-8. PubMed ID: 24842383
[No Abstract] [Full Text] [Related]
9. [Basal insulin has a "neutral effect" on cardiovascular events].
Overbeck P
MMW Fortschr Med; 2012 Jun; 154(12):24. PubMed ID: 22880290
[No Abstract] [Full Text] [Related]
10. Metabolic surgery and intestinal gene expression: Digestive tract and diabetes evolution considerations.
Rodrigues MR; Santo MA; Favero GM; Vieira EC; Artoni RF; Nogaroto V; de Moura EG; Lisboa P; Milleo FQ
World J Gastroenterol; 2015 Jun; 21(22):6990-8. PubMed ID: 26078577
[TBL] [Abstract][Full Text] [Related]
11. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
12. New Therapeutic Strategies for Type 2 Diabetes
Yehya A; Sadhu AR
Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014
[TBL] [Abstract][Full Text] [Related]
13. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
[TBL] [Abstract][Full Text] [Related]
14. Decrease mortality in type II diabetes mellitus: glycemic and renal function control.
Borghi C; Ventura F
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e13-e15. PubMed ID: 29538138
[No Abstract] [Full Text] [Related]
15. Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications.
Abdul-Ghani MA; Jayyousi A; DeFronzo RA; Asaad N; Al-Suwaidi J
Curr Vasc Pharmacol; 2019; 17(2):153-163. PubMed ID: 29032755
[TBL] [Abstract][Full Text] [Related]
16. Glucose lowering strategies and cardiovascular disease in type 2 diabetes - teachings from the TOSCA.IT study.
Vaccaro O; Masulli M; Riccardi G
Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):722-726. PubMed ID: 29804832
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
Torekov SS
Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
[No Abstract] [Full Text] [Related]
18. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
Wareham NJ; Pfister R
Nat Rev Cardiol; 2010 Jul; 7(7):367-8. PubMed ID: 20577298
[TBL] [Abstract][Full Text] [Related]
19. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
[TBL] [Abstract][Full Text] [Related]
20. Novo Nordisk incretin and Cardiovascular Summit, Durban, June 2013.
Wagenaar P
Cardiovasc J Afr; 2013 Sep; 24(8):340. PubMed ID: 24240386
[No Abstract] [Full Text] [Related]
[Next] [New Search]
